Table A1 Associations of intermediate frailty risk with adverse clinical outcomes compared to the low frailty risk group.

	Intermediate Risk, OR (95% CI), P-value						
Outcome	unadjusted	Model 1	Model 2	Model 3	NEWS-adjusted		
all-cause 30-day mortality	2.53 (2.09 to 3.06), p<0.001	2.45 (2.03 to 2.97), p<0.001	2.52 (2.08 to 3.06), p<0.001	2.65 (2.17 to 3.25), p<0.001	2.05 (1.69 to 2.50), p<0.001		
Length of stay, median (IQR)*	3.74 (3.34 to 4.14), p<0.001	3.76 (3.36 to 4.16), p<0.001	3.83 (3.45 to 4.21), p<0.001	3.77 (3.39 to 4.15), p<0.001	3.69 (3.28 to 4.09), p<0.001		
Long hospital stay >10 days	3.47 (2.99 to 4.02), p<0.001	3.50 (3.02 to 4.06), p<0.001	3.55 (3.06 to 4.12), p<0.001	3.66 (3.14 to 4.28), p<0.001	3.44 (2.96 to 3.99), p<0.001		
30-day readmission	sion 1.04 (0.88 to 1.24), p=0.643 1.06 (0.89 to 1.26), p=0.521 1.06 (0.89 to 1.26), p=0.503		1.06 (0.89 to 1.26), p=0.503	1.04 (0.87 to 1.24), p=0.69	0.99 (0.83 to 1.18), p=0.883		
Functional impairment, n (%)							
Barthel Index, median (IQR)*	-15.76 (-17.87 to -13.64), p<0.001	-15.01 (-17.1 to -12.92), p<0.001	-14.87 (-16.97 to -12.78), p<0.0010	-14.59 (-16.69 to -12.48), p<0.001	-15.45 (-17.59 to -13.31), p<0.001		
Barthel Index <95 points	2.98 (2.48 to 3.58), p<0.001	2.89 (2.4 to 3.47), p<0.001	2.85 (2.36 to 3.43), p<0.001	2.87 (2.37 to 3.47), p<0.001	2.87 (2.38 to 3.45), p<0.001		
Quality of Life, n(%)							
Impairment of mobility	3.25 (2.59 to 4.08), p<0.001	3.14 (2.50 to 3.95), p<0.001	3.13 (2.49 to 3.94), p<0.001	3.1 (2.46 to 3.92), p<0.001	3.17 (2.52 to 3.99), p<0.001		
Impairment of self-care	3.69 (3.07 to 4.44), p<0.001	3.60 (2.99 to 4.35), p<0.001	3.56 (2.95 to 4.30), p<0.001	3.63 (2.99 to 4.4), p<0.001	3.55 (2.95 to 4.28), p<0.001		
Impairment of usual activities	2.51 (2.08 to 3.05), p<0.001	2.41 (1.99 to 2.93), p<0.001	2.35 (1.93 to 2.87), p<0.001	2.35 (1.92 to 2.87), p<0.001	2.45 (2.02 to 2.98), p<0.001		
Pain/discomfort	1.25 (1.04 to 1.51), p=0.017	1.26 (1.04 to 1.51), p=0.015	1.22 (1.01 to 1.47), p=0.036	1.21 (1 to 1.47), p=0.047	1.29 (1.07 to 1.55), p=0.008		
Anxiety/depression	1.26 (1.03 to 1.55), p=0.023	1.28 (1.04 to 1.56), p=0.018	1.25 (1.02 to 1.53), p=0.032	1.26 (1.02 to 1.55), p=0.029	1.22 (1.00 to 1.50), p=0.053		
EQ-VAS, mean (SD)*	-3.9 (-5.83 to -1.97), p<0.001	-3.87 (-5.81 to -1.93), p<0.001	-3.78 (-5.73 to -1.84), p<0.001	-3.75 (-5.69 to -1.81), p<0.001	-3.57 (-5.52 to -1.61), p<0.001		
discharge other than home	2.46 (2.13 to 2.83), p<0.001	2.39 (2.07 to 2.75), p<0.001	2.39 (2.07 to 2.75), p<0.001	2.53 (2.18 to 2.92), p<0.001	2.15 (1.86 to 2.48), p<0.001		

95% CI confidence interval; EQ-VAS EuroQol visual analog health scale; IQR interquartile range; NEWS national early warning score; OR odds ratio; SD standard deviation; Quality of life measures were adapted from EQ-5D. We dichotomized levels into "no impairment" (level 1) and "impairment" (levels 2 and 3). Frequencies of reported impairment (level 2 and 3) were analyzed. Models were adjusted for age (model 1), age and gender (model 2), age, gender, and comorbidities not included in the score (model 3), and for NEWS which was calculated retrospectively based on admission data.

* linear regression analyses were calculated reporting regression coefficient, 95% confidence interval, P-value

Table A2 Associations of high frailty risk with adverse clinical outcomes compared to the low frailty risk group.

	High Risk, OR (95% CI), P-value					
Outcome	unadjusted	Model 1	Model 2	Model 3	NEWS adjusted	
all-cause 30-day mortality	4.40 (2.94 to 6.57), p<0.001	4.28 (2.86 to 6.41), p<0.001	4.49 (2.99 to 6.73), p<0.001	4.83 (3.17 to 7.37), p<0.001	3.68 (2.41 to 5.60), p<0.001	
Length of stay, median (IQR)*	10.04 (8.92 to 11.16), p<0.001	10.06 (8.94 to 11.18), p<0.001	10.12 (9.06 to 11.19), p<0.001	10.07 (9.02 to 11.13), p<0.001	9.98 (8.86 to 11.10), p<0.001	
Long hospital stay >10 days	9.21 (6.51 to 13.01), p<0.001	9.28 (6.56 to 13.12), p<0.001	9.42 (6.66 to 13.33), p<0.001	9.75 (6.83 to 13.92), p<0.001	9.10 (6.43 to 12.88), p<0.001	
30-day readmission	1.47 (0.95 to 2.26), p=0.081	1.49 (0.97 to 2.29), p=0.070	1.49 (0.97 to 2.30), p=0.069	1.67 (1.08 to 2.59), p=0.022	1.38 (0.90 to 2.13), p=0.141	
Functional impairment, n (%)						
Barthel Index, median (IQR)*	-40.55 (-47.01 to -34.09), p<0.001	-40.29 (-46.66 to -33.93), p<0.001	-40.01 (-46.37 to -33.64), p<0.001	-39.70 (-46.06 to -33.33), p<0.001	-40.06 (-46.54 to -33.58), p<0.001	
Barthel Index <95 points	22.37 (8.04 to 62.23), p<0.001	23.74 (8.48 to 66.44), p<0.001	22.9 (8.19 to 64.06), p<0.001	25.03 (8.91 to 70.32), p<0.001	21.12 (7.58 to 58.83), p<0.001	
Quality of Life, n(%)						
Impairment of mobility	8.61 (4.97 to 14.91), p<0.001	8.62 (4.95 to 15.01), p<0.001	8.57 (4.92 to 14.93), p<0.001	8.45 (4.82 to 14.81), p<0.001	8.29 (4.77 to 14.40), p<0.001	
Impairment of self-care	9.40 (4.70 to 18.79), p<0.001	9.67 (4.8 to 19.48), p<0.001	9.39 (4.66 to 18.90), p<0.001	9.59 (4.74 to 19.41), p<0.001	8.85 (4.42 to 17.73), p<0.001	
Impairment of usual activities	4.16 (2.08 to 8.31), p<0.001	4.19 (2.08 to 8.44), p<0.001	3.88 (1.92 to 7.82), p<0.001	3.98 (1.97 to 8.06), p<0.001	4.00 (2.00 to 8.00), p<0.001	
Pain/discomfort	1.39 (0.77 to 2.52), p=0.278	1.39 (0.77 to 2.52), p=0.276	1.28 (0.70 to 2.34), p=0.413	1.28 (0.70 to 2.33), p=0.430	1.45 (0.80 to 2.63), p=0.225	
Anxiety/depression	3.29 (1.73 to 6.26), p<0.001	3.29 (1.73 to 6.27), p<0.001	3.08 (1.61 to 5.89), p=0.001	3.11 (1.62 to 5.99), p=0.001	3.11 (1.63 to 5.95), p=0.001	
EQ-VAS, mean (SD)*	-10.3 (-17.53 to -3.08), p=0.005	-10.3 (-17.53 to -3.07), p=0.005	-10.13 (-17.37 to -2.90), p=0.006	-11.12 (-18.29 to -3.94), p=0.002	-9.77 (-17.01 to -2.54), p=0.008	
discharge other than home	3.54 (2.50 to 5.01), p<0.001	3.46 (2.44 to 4.90), p<0.001	3.46 (2.44 to 4.90), p<0.001	3.81 (2.68 to 5.42), p<0.001	3.09 (2.17 to 4.41), p<0.001	

95% CI confidence interval; EQ-VAS EuroQol visual analog health scale; IQR interquartile range; NEWS national early warning score; OR odds ratio; SD standard deviation; Quality of life measures were adapted from EQ-5D. We dichotomized levels into "no impairment" (level 1) and "impairment" (levels 2 and 3). Frequencies of reported impairment (level 2 and 3) were analyzed. Models were adjusted for age (model 1), age and gender (model 2), age, gender, and comorbidities not included in the score (model 3), and for NEWS which was calculated retrospectively based on admission data.

* linear regression analyses were calculated reporting regression coefficient, 95% confidence interval, P-value

Table A3 ROC analyses of different frailty score cut-offs for the outcome 30-day mortality

	low risk	inte	ermediate risk		high risk	AUC (95% CI)
Cut-off	No of patients	Cut-off	No of patients	Cut-off	No of patients	
	63.55 %	5-15	33.55 %	>15	2.9 %	0.624 (0.601 to 0.647)
<5	63.55 %	5-10	24.69 %	>10	11.76 %	0.629 (0.605 to 0.652)
<4	55.09 %	4-10	33.15 %	>10	11.76 %	0.636 (0.613 to 0.660)
<4	55.09 %	4-9	30.18 %	>9	14.73 %	0.637 (0.613 to 0.660)

AUC, area under the receiver operating curve; 95% CI, 95% confidence interval